PSCA-Targeted CAR Architecture for Selective Prostate Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Designing a chimeric antigen receptor (CAR) that effectively targets prostate cancer cells while minimizing activity against non-cancerous cells and avoiding off-tumor effects, such as cytokine production, is challenging due to the expression of prostate stem cell antigen (PSCA) in both cancerous and normal tissues, and the immunosuppressive microenvironment of solid tumors.
Innovation Solution
The development of a CAR comprising an extracellular domain with a PSCA-specific scFv, a transmembrane region, and an intracellular signaling domain, including a costimulatory domain like CD28 or 4-1BB, which is expressed on T cells to enhance anti-tumor activity while avoiding off-target effects, using a spacer region derived from human IgG4 Fc domain to improve specificity and using CD4 or CD8 transmembrane domains for enhanced cell persistence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a CAR targeting PSCA is designed to effectively kill prostate cancer cells, then anti-tumor efficacy is improved, but off-target activity against non-cancerous cells expressing low levels of PSCA increases
Solution Approach 1:
The patent modifies the activation threshold parameter of the CAR by requiring dual signaling (antigen binding plus costimulatory signal) for full T cell activation. This parameter change ensures that only cells with high PSCA expression (cancer cells) can activate the CAR, while cells with low PSCA expression (normal cells) cannot trigger sufficient signaling, thereby improving therapeutic index
Solution Approach 2:
The patent introduces an intermediary costimulatory domain (CD28 or 4-1BB) between the antigen recognition domain and the signaling domain. This intermediary requires simultaneous engagement of both the PSCA antigen and the costimulatory receptor, creating a dual-checkpoint mechanism that prevents activation against normal cells while maintaining efficacy against cancer cells
2Productivity
If the CAR is designed with high activation sensitivity to target cancer cells, then tumor cell killing is improved, but cytokine production and off-tumor effects increase
Solution Approach 1:
The patent applies preliminary anti-action by designing the CAR structure to prevent excessive cytokine production before it occurs. The costimulatory domain requirement acts as a preliminary control mechanism that ensures cytokines are only produced when both antigen and costimulatory signals are present, preventing premature or excessive immune activation that would lead to harmful cytokine storms
3Productivity
If a CAR with strong effector function is used to achieve robust anti-tumor response, then tumor clearance is improved, but T cell persistence and replicative capacity decrease
Solution Approach 1:
The patent employs dynamics by selecting different costimulatory domains (CD28 for rapid activation, 4-1BB for sustained persistence) and combining them with antigen recognition to create a balanced activation profile. This dynamic approach allows the CAR T cells to exhibit strong effector function initially while maintaining long-term persistence through the selected costimulatory signaling pathway
Data Source
AI summary
Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.